Straumann® Emdogain®

a promoter of soft and hard tissue regeneration

 

SStraumann® Emdogain® is a well-researched, easy-to-apply gel containing enamel matrix derivative originating from unerupted porcine tooth buds. As a component of embryonic tissues it is designed to promote predictable regeneration of hard and soft tissues lost due to periodontal disease or trauma.

The main component in Straumann® Emdogain® is amelogenin, which assembles into an insoluble matrix under physiological conditions. The matrix has the proven ability to stimulate various cell types involved in the wound healing cascade of soft and hard tissues (mesenchymal stem cells, osteoblasts, fibroblasts, periodontal ligament cells and cementoblasts) towards a regenerative pattern.
 

Combination with bone grafts

 

The product may be ideally combined to enhance the biological performance of bone graft materials, like maxresorb® and cerabone® and collagen products like the mucoderm® or Jason® membrane [1,2].

emdogain_01
1-wall intrabony defect before and eight years after periodontal regeneration with Emdogain® (Dr. G. Heden, Karlstad, Sweden)

emdogain_02
Intraosseous defect before and two years after treatment with  Emdogain® (Dr. J. Doobrow, Cullman-Al, USA)

Picture with capillaries:
Emdogain® stimulates angiogenesis (Prof. M. Ågren, Copenhagen, Denmark)

CLINICAL APPLICATION

Two-wall intrabony defect treated using cerabone® and Straumann® Emdogain®

Dr. Dragana Rakasevic
Prof. Dr. Sasa Jankovic
School of Dental Medicine,
University of Belgrade, Serbia

Multiple gingival recessions treated with the coronally advanced flap in conjunction with mucoderm® and Straumann® Emdogain®

Prof. Dr. Dr. Adrian Kasaj
Department of Operative Dentistry and Periodontology,

University of Mainz, Germany

Multiple gingival recessions treated with the modified coronally advanced flap in conjunction with mucoderm® and Straumann® Emdogain®

Dr. David B. Hangyási
Dentalstory Private Practice, Hódmezővásárhely, Hungary
;
University of Szeged, Hungary

PROPERTIES

  • Induces true periodontal regeneration as evidenced by human histological studies [3,4]
  • Easy to apply in difficult accessible defects and in minimal invasive procedures
  • Shows less complications compared to membranes [5]
  • Well researched and published in 800 scientific and 200 clinical publications
  • Based on ten-year long-term evidence in intrabony and recession defects [6,7]
  • Stimulates bone formation and angiogenesis [8,9]
  • Available in three different volume sizes allowing flexible treatment options

UPCOMING EVENTS

Dresden, 19. Aug. 2017

Prof. Dr. med. dent., Dr. h.c. mult. Anton Sculean, M.Sc.: Innovative Konzepte

Manila, 12-13 Sep. 2017

 

More Events on botiss-academy

VIDEOS

Less pain less swelling

 

Aesthetics

 

Less complications

 

Clinical results

 

SPECIFIC DETAILS

SPECIFIC FACTS

Bioactive protein matrix

Following application, the bioactive components (amelogenins) of Straumann® Emdogain® immediately precipitate to form an insoluble protein layer on the root surface, which stimulates several different cell types involved in tissue repair. To ensure an optimal protein precipitation, the dentin surface should ideally be free from blood and saliva.

Straumann® PrefGel®

Straumann® PrefGel is an EDTA-containing gel that is used to remove the smear layer on the exposed dentin surface and to provide optimal binding conditions of the bioactive components of Straumann® Emdogain® and the blood clot to the root surface. Straumann® PrefGel® is pH neutral, which minimizes necrosis of adjacent tissues.

Syringe sizes

The 0.15 ml size is suitable for single defects, e.g. a narrow intrabony defect or an isolated gingival recession. Straumann® Emdogain® 0.3 ml is suitable for a wide or larger single defect and where additional regenerative material (bone grafts) may be used. The 0.7 ml size is suitable for wide defects and is sufficient for two to three defects.

Retention of Straumann® Emdogain® gel

The bioactive components (amelogenins) of Straumann® Emdogain® are dissolved in a carrier substance (Propylene Glycol Alginate, PGA). Following application, the amelogenins immediately precipitate to form an insoluble protein layer on the root surface while most of the carrier leaves the defect. Thus, a retention of Straumann® Emdogain® after application is not necessary.

Barrier membrane

Straumann® Emdogain® is a stand-alone procedure that induces de-novo formation of all periodontal tissues and can be used without a barrier membrane. There is currently no evidence that the combined use of Straumann® Emdogain® and a membrane improves the clinical outcome.

Combined use with bone grafts

Wide contained and non-contained periodontal bone defects usually require additional volume support in order to prevent flap collapse. In these cases the additional use of bone grafts is recommended as they provide space for the regenerative process. Controlled clinical studies demonstrate the combined use of Straumann® Emdogain® and particulate bone grafting material of different origin (autologous, allogenic, xenogeneic, alloplastic). Straumann® Emdogain® may also be mixed with the granules prior to the application when additional bone grafts are used.

Splinting

Teeth with a mobility grade > 1 should always be splinted six to eight weeks after the periodontal treatment with Straumann® Emdogain® and ideally also before the treatment, because the mobility affects the regenerative process. The splint should not touch the gingiva.

Let us know YOUR COUNTRY and we will provide you with YOUR right local CONTACT PERSON!

Email to product-management@botiss.com!

PRODUCT SPECIFICATIONS

NEW SIZES:

Art.-No. Product Content
075.098W Straumann® Emdogain® 0,15 ml 5 x 0,15 ml Emdogain®
075.101W Straumann® Emdogain® 0,3 ml 1 x 0,3 ml Emdogain®
075.102W Straumann® Emdogain® 0,7 ml 1 x 0,7 ml Emdogain®
 075.114W  Straumann® Emdogain® 0,3 ml Multipack  3 x 0,3 ml Emdogain®
3 x 0,6 ml PrefGel®
 075.116W  Straumann® Emdogain® 0,7 ml Multipack  3 x 0,7 ml Emdogain®
3 x 0,6 ml PrefGel®
 075.127W  Straumann® Emdogain® 0,15 ml  1 x 0,15 ml Emdogain®
 075.128W  Straumann® Emdogain® 0,3 ml  5 x 0,3 ml Emdogain®
 075.129W  Straumann® Emdogain® 0,7 ml  5 x 0,7 ml Emdogain®
 075.203W  Straumann® PrefGel®  5 x 0,6 ml PrefGel®

Articles

  • Cairo F, Pagliaro U, Nieri M. Treatment of gingival recession with coronally advanced flap procedures: a systematic review. J Clin Periodontol. 2008 Sep;35(8 Suppl):136-62. LINK
  • Lyngstadaas SP, Wohlfahrt JC, Brookes SJ, Paine ML, Snead ML, Reseland JE. Enamel matrix proteins; old molecules for new applications. Orthod Craniofac Res. 2009 Aug;12(3):243-53. LINK
  • Miron RJ, Sculean A, Cochran DL, Froum S, Zucchelli G, Nemcovsky C, Donos N, Lyngstadaas SP, Deschner J, Dard M, Stavropoulos A, Zhang Y, Trombelli L, Kasaj A, Shirakata Y, Cortellini P, Tonetti M, Rasperini G, Jepsen S, Bosshardt DD. Twenty years of enamel matrix derivative: the past, the present and the future. J Clin Periodontol. 2016 Aug;43(8):668-83. LINK
  • Sculean A. Alessandri R. Miron R. Salvi GE. Bosshardt DD. Enamel Matrix Proteins and Periodontal Wound Healing and Regeneration. Clin Adv Periodontics 2011; 1:101-117. LINK
LITERATURE

[1] Shirakata et al. Clin Oral Invest. 2016
[2] Stähli et al. J Periodont 2016
[3] Sculean et al. J Periodontal Res 1999

[4] Heijl et al. J Clin Periodontol 1997
[5] Jepsen et al. J Periodont 2004
[6] McGuire et al. J Periodont 2012

[7] Sculean et al. J Clin Periodontol 2008
[8] Miron et al. Clin Oral Invest. 2014
[9] Kasaj et al. J Periodontal Res. 2012